Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Carbery

David J. Carbery, Vashon, WA US

Patent application numberDescriptionPublished
20110073238COMPOSITE MATERIAL PLACEMENT METHOD AND SYSTEM - To apply a course on a layup mold, a ply boundary that defines a ply area on the layup mold is determined and a tape of composite material is applied on the ply area at an oblique angle relative to the ply boundary. In addition, a leading edge of the tape is butt cut and the leading edge, and the ply boundary essentially converge. Furthermore, a trailing edge is generated. The trailing edge is a butt cut and the trailing edge and the ply boundary essentially converge.03-31-2011

Desmond Carbery, Dublin IE

Patent application numberDescriptionPublished
20100211961DATA BUS BETWEEN MIDDLEWARE LAYERS - A system/method is introduced that integrates middleware components without canonicalization of data at runtime, where the system/method receives inputs identifying at least a first and second middleware to be made interoperative (via a communication path between an in-port corresponding to the first middleware and an out-port corresponding to the second middleware), receives an incoming message at the in-port, handles the received message as a plurality of parts and where, for each part, a data-object is created based on an identified type factory, with the in-port populating the data-object with values from corresponding part of the message and passing the populated data object from the in-port corresponding to the first middleware to the out-port corresponding to the second middleware.08-19-2010

Rachel Jane Carbery, Trowbridge GB

Patent application numberDescriptionPublished
20090264411FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS - A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.10-22-2009